Evidence map›Paper›PMID 39404914›Full record

ReviewHeart failure reviews2025

In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure.

Muhammad Sameer Arshad, Adeena Jamil, Stephen J Greene, Harriette G C Van Spall, Gregg C Fonarow, Javed Butler, Muhammad Shahzeb Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad Sameer ArshadDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Adeena JamilDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Stephen J GreeneDuke Clinical Research Institute, Durham, NC, USA.
Harriette G C Van SpallFaculty of Health Science, McMaster University, Hamilton, Canada Population Health Research Institute, Hamilton, Canada.
Gregg C FonarowAhmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, CA, USA.
Javed ButlerDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Muhammad Shahzeb KhanBaylor Scott and White Research Institute, Dallas, TX, USA. shahzebkhan@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD), regardless of diabetes status and left ventricular ejection fraction (LVEF). Despite robust data demonstrating the efficacy of SGLT-2 inhibitors in both ambulatory and hospital settings, real-world evidence suggests slow and varied adoption of SGLT2 inhibitors among patients hospitalized for HF. Barriers to implementation of SGLT2i may include clinicians' concerns regarding potential adverse events such as diabetic ketoacidosis (DKA), volume depletion, and symptomatic hypoglycemia; or concerns regarding physiologically expected reductions in eGFR. Guidelines lack specific, practical safety data and definitive recommendations regarding in-hospital initiation and continuation of SGLT2i in patients hospitalized with HF. In this review, we discuss the safety of in-hospital SGLT2 inhibitor initiation based on recent trials and highlight the clinical implications of their early use in patients hospitalized for HF.

Indexed as

Heart FailureHospitalizationSodium-Glucose Transporter 2 InhibitorsAcute DiseaseDiabetes Mellitus, Type 2HumansSodium-Glucose Transporter 2 InhibitorsAcute heart failureAdverse eventsDiabetic ketoacidosisGenital yeast infectionsIn-hospital initiationSodium-glucose cotransporter-2 inhibitors

Identifiers

PMID39404914

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.